|
|
|
As filed with the Securities and Exchange Commission on December 3, 2010
|
|
File No. 333-128030 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1
TO
FORM S-3
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
ONCOGENEX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
(State or other jurisdiction of incorporation or
organization)
|
|
95-4343413
(I.R.S. Employer Identification No.) |
1522 217th Place SE, Suite 100
Bothell, Washington 98021
(425) 686-1500
(Address, including zip code, and telephone number, including area code, of registrants principal executive offices)
Scott Cormack
Chief Executive Officer
1522 217th Place SE, Suite 100
Bothell, Washington 98021
(425) 686-1500
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Christopher L. Doerksen
Dorsey & Whitney LLP
Columbia Center
701 Fifth Avenue, Suite 6100
Seattle, WA 98104
Tel: (206) 903-8800
Approximate date of commencement of proposed sale to the public: From time to time after the
effective date of this Registration Statement.
If the only securities being registered on this Form are being offered pursuant to dividend or
interest reinvestment plans, please check the following box: o
If any of the securities being registered on this Form are to be offered on a delayed or
continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities
offered only in connection with dividend or interest reinvestment plans, check the following box:
o
If this Form is filed to register additional securities for an offering pursuant to Rule
462(b) under the Securities Act, please check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same
offering: o
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities
Act, check the following box and list the Securities Act registration statement number of the
earliest effective registration statement for the same offering: o
If this Form is a registration statement pursuant to General Instruction I.D. or a
post-effective amendment thereto that shall become effective upon filing with the Commission
pursuant to Rule 462(e) under the Securities Act, check the following box. o
If this Form is a post-effective amendment to a registration statement filed pursuant to General
Instruction I. D. filed to register additional securities or additional classes of securities
pursuant to Rule 413(b) under the Securities Act, check the following box. o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large
accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the
Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated filer o
|
|
Accelerated filer þ
|
|
Non-accelerated filer o
|
|
Smaller reporting company o |
(Do not check if a smaller reporting company)
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant
certifies that it has reasonable grounds to believe that it meets all of the requirements for
filing on Form S-3 and has duly caused this Post-Effective Amendment No. 1 to the Registration
Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of
Bothell, State of Washington, on December 2, 2010.
|
|
|
|
|
|
ONCOGENEX PHARMACEUTICALS, INC.
|
|
|
/s/ Scott Cormack
|
|
|
Scott Cormack |
|
|
President and Chief Executive Officer |
|
|
Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective
Amendment No. 1 to the Registration Statement has been signed by the following persons in the
capacities and on the dates indicated.
|
|
|
|
|
Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/ Scott Cormack
Scott Cormack
|
|
President, Chief Executive Officer and Director
(Principal Executive Officer)
|
|
December 2, 2010 |
|
|
|
|
|
/s/ Cameron Lawrence
Cameron Lawrence
|
|
Principal Financial Officer
(Principal Financial and Accounting Officer)
|
|
December 2, 2010 |
|
|
|
|
|
/s/ Jack Goldstein
Jack Goldstein
|
|
Director
|
|
December 2, 2010 |
|
|
|
|
|
/s/ Michelle G. Burris
Michelle G. Burris
|
|
Director
|
|
December 2, 2010 |
|
|
|
|
|
/s/ Neil Clendeninn
Neil Clendeninn
|
|
Director
|
|
December 2, 2010 |
|
|
|
|
|
/s/ Martin Mattingly
Martin Mattingly
|
|
Director
|
|
December 2, 2010 |
|
|
|
|
|
/s/ Stewart Parker
Stewart Parker
|
|
Director
|
|
December 2, 2010 |
|
|
|
|
|
/s/ David Smith
David Smith
|
|
Director
|
|
December 2, 2010 |
-3-